Dasatinib Could Increase Risk for Pulmonary Hypertension.
Posted 08 February 2012 - 12:54 PM
The FDA has warned that dasatinib (Sprycel, Bristol-Myers Squibb) may increase the risk for pulmonary arterial hypertension (PAH). Dasatinib is used to treat certain types of leukemia, and is sometimes used off-label for other cancers. TheHeart.org, Dec. 2012. (Also see: Causes of Pulmonary Hypertension)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
ISN Assistant Webmaster
SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager
ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)